Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation. by Juanita K. Hodax (6848540)

Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study by Kelly Fellows Maxwell (6852752)

“…At 12 months, increases in HDL-C (mean change: +6.0 mg/dl; 95% CI: 0.3, 12.0; p = 0.049) and decreases in BMI (mean change: -2.6 kg/m²; 95% CI: -3.6, -2.5; p < 0.001), LDL-C (mean change: -10.4 mg/dl; 95% CI:-19.7, -1.2; p = 0.029), TG (mean change: -29.2 mg/dl; 95% CI: -44.3, -14.2; p = 0.001), TG to HDL-C ratio (mean change: -0.6; 95% CI: -1.0, -0.3; p = 0.002) and TC to HDL-C ratio (mean change:-0.6; 95% CI: -1.0, -0.3; p = 0.003) were observed compared to baseline. …”

A flow diagram of the study entry. by Sakiko Fukui (387048)

Subjects:

Yta4 decreases the affinity of Dnm1 for GTP. by Jiajia He (795335)

Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Treatment of NCI-H1975 cell-transplanted mice with erastin showed a tendency of sensitization to X-ray irradiation with a decrease in glutathione concentration. by Yuki Shibata (5094866)

General patient characteristics. by Ekaterina A. Bryushkova (13360122)

Subjects:

Individual dynamics of blood parameters. by Ekaterina A. Bryushkova (13360122)

Subjects:

Baseline clinical characteristics of patients. by Ekaterina A. Bryushkova (13360122)

Subjects:

Changes in CRP and LDH levels over time. by Ekaterina A. Bryushkova (13360122)

Subjects:

Minimal dataset. by Ekaterina A. Bryushkova (13360122)

Subjects:

The outcome timepoints and the mortality level of patients. by Ekaterina A. Bryushkova (13360122)

Subjects:

VPA decreases cell proliferation. by Muriel Rhinn (406515)

Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

Subjects:

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Post-losartan treatment prevented SARS-CoV-2 spike protein-induced decreased cognitive impairment but not pre-losartan treatment. by Mackenzi Meier (19251139)

Procedures of sampling and measurements. by Xuegang Mao (599968)

Subjects:

Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

“…The data displayed in (D), (E), (G), and (H) can be found in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003421#pbio.3003421.s001" target="_blank">S1 Fig</a>.…”

Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

“…Colors indicate samples from different animals. Large circles show mean of cells from 5 fields of view from a single animal. …”